Two Shares Head to Head: Domtar Corporation (NYSE:UFS), Nektar Therapeutics (NASDAQ:NKTR)

u.s stocks , earnings estimates, stock overview, earning reaction history, nasdaq, nyse

Domtar Corporation (NYSE:UFS)

Domtar Corporation (NYSE:UFS) closed at $34.42 on the last trading session with an decrease of -4.5%, whereas, it previously closed at $36.04. The company has a market capitalization of $2.12 Billion. The company traded shares of 814922 on the trading day while its three month average volume stands at 728.05 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Domtar Corporation (NYSE:UFS) produced diluted EPS of 3.16. The EPS estimate for next year as estimated by analysts is at 3.1 while EPS for next quarter is estimated at 0.54. Earnings per Share growth for this year is reported at 169.2, while the analysts estimated the EPS growth for next year at 3.1% and Earnings growth for next 5 years stands at 5% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 26.4%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Domtar Corporation (NYSE:UFS) is at 10.91 while the forward p/e is at 11.11. The P/S or Price to Sales ratio of Domtar Corporation (NYSE:UFS) stands at 0.39 and Price to Book or P/B for the most recent quarter stands at 0.87. The Price to Free Cash Flow ratio or P/FCF is reported at 18.08. The quick ratio and the current ratio of Domtar Corporation (NYSE:UFS) are reported at 1.1 and 2.3 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Domtar Corporation (NYSE:UFS) stands at 5.7, 11.1 and 9.5 respectively

The trailing twelve month Revenue of Domtar Corporation (NYSE:UFS) is reported at 5.37 Billion with income of 199 Million. The outstanding shares of Domtar Corporation (NYSE:UFS) are 61.47 Million. The institutional Ownership of the shares of 99.6 stands at 0.80%, this figure is increased 1.61 in the last six months. The insider ownership for the shares of Domtar Corporation (NYSE:UFS) is ticked at 0.14%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for Domtar Corporation (NYSE:UFS) is the Mean Target Price estimated by the analysts which stands at 40.21. The 52 week high of Domtar Corporation (NYSE:UFS) is placed at 53.89 and 52 week low is standing at 31.72.

Performance wise the shares of Domtar Corporation (NYSE:UFS) fell down -5.21% for the week, it also fell -10.76% for the monthly performance, while for the quarter it went up -10.18%. The shares increase 1.47% for the half year and plummeted for the Year-To-Date performance. The shares of Domtar Corporation (NYSE:UFS) shrinked -33.17% for the yearly performance.

Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) closed at $22.85 on the last trading session with an decrease of -2.66%, whereas, it previously closed at $23.48. The company has a market capitalization of $4.06 Billion. The company traded shares of 1.17 Million on the trading day while its three month average volume stands at 2.52 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Nektar Therapeutics (NASDAQ:NKTR) produced diluted EPS of -2.44. The EPS estimate for next year as estimated by analysts is at -2.43 while EPS for next quarter is estimated at -0.68. Earnings per Share growth for this year is reported at 289.5, while the analysts estimated the EPS growth for next year at -2.43% and Earnings growth for next 5 years stands at -7.3% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 36.3%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Nektar Therapeutics (NASDAQ:NKTR) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of Nektar Therapeutics (NASDAQ:NKTR) stands at 33.63 and Price to Book or P/B for the most recent quarter stands at 2.69. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Nektar Therapeutics (NASDAQ:NKTR) are reported at 12.5 and 12.6 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Nektar Therapeutics (NASDAQ:NKTR) stands at -20, -26.6 and 34.9 respectively

The trailing twelve month Revenue of Nektar Therapeutics (NASDAQ:NKTR) is reported at 120.6 Million with income of -425400000. The outstanding shares of Nektar Therapeutics (NASDAQ:NKTR) are 177.48 Million. The institutional Ownership of the shares of 0 stands at 0.80%, this figure is decreased -0.44 in the last six months. The insider ownership for the shares of Nektar Therapeutics (NASDAQ:NKTR) is ticked at 1.3%, the figure is plummeted -11.16% in the last six months.

Some other important financial aspects to be discussed here for Nektar Therapeutics (NASDAQ:NKTR) is the Mean Target Price estimated by the analysts which stands at 34.23. The 52 week high of Nektar Therapeutics (NASDAQ:NKTR) is placed at 44.06 and 52 week low is standing at 15.64.

Performance wise the shares of Nektar Therapeutics (NASDAQ:NKTR) rose up 0.18% for the week, it also fell -18.28% for the monthly performance, while for the quarter it went down 12.31%. The shares increase 22.06% for the half year and flew up for the Year-To-Date performance. The shares of Nektar Therapeutics (NASDAQ:NKTR) shrinked -45.92% for the yearly performance.